Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Kalaris Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 90
- −4 vs. Q2 2023
- Shares held
- 53.7M
- −278.0K (−0.5%) vs. Q2 2023
- Total value
- $115.5M
- −$68.1M (−37.1%) vs. Q2 2023
- New holders
- 14
- 40 more added
- Sold out
- 18
- 20 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KLRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 56 | $73.4M |
| Q1 2026 | 58 | $107.2M |
| Q4 2025 | 51 | $151.9M |
| Q3 2025 | 32 | $76.4M |
| Q2 2025 | 30 | $35.7M |
| Q1 2025 | 32 | $111.4M |
| Q4 2024 | 53 | $20.7M |
| Q3 2024 | 60 | $36.3M |
| Q2 2024 | 72 | $33.9M |
| Q1 2024 | 77 | $36.4M |
| Q4 2023 | 82 | $28.5M |
| Q3 2023 | 90 | $115.5M |
| Q2 2023 | 94 | $183.6M |
| Q1 2023 | 89 | $156.0M |
| Q4 2022 | 86 | $193.1M |
| Q3 2022 | 87 | $293.7M |
| Q2 2022 | 84 | $109.6M |
| Q1 2022 | 84 | $184.1M |
| Q4 2021 | 84 | $329.4M |
| Q3 2021 | 80 | $640.3M |
| Q2 2021 | 84 | $521.8M |
| Q1 2021 | 75 | $624.4M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Kalaris Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| State Board of Administration of Florida Retirement System | 0 | $0 | 0.00% | −11,900−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −8,150−100.0% | Sold out |
| Denali Advisors LLC | 0 | $0 | 0.00% | −6,500−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −5,958−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −3,261−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −639−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| EverSource Wealth Advisors, LLC | 0 | $0 | 0.00% | −159−100.0% | Sold out |